Torrent Pharmaceuticals Board Meeting Scheduled on May 22, 2026 to Consider FY26 Audited Results and Dividend

Torrent Pharmaceuticals has notified the stock exchanges of an upcoming Board of Directors meeting scheduled for Friday, May 22, 2026, pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation was filed on May 9, 2026, and signed by Company Secretary Chintan M Trivedi.

Key Agenda Items for the Board Meeting

The Board meeting has been convened to address several significant matters. The following table outlines the key agenda items scheduled for deliberation:

Agenda Item: Details Financial Results: Audited Financial Results for the year ended March 31, 2026 Dividend Consideration: Recommendation of final dividend, if any, on equity shares for the year 2025-26 Fund Raising: Enabling resolutions for raising funds via QIP, Convertible Bonds/Debentures, Depository Receipts, or other modes Shareholder Approval: Fund-raising resolution, if approved by Board, to be placed before shareholders at the ensuing AGM

Audited Financial Results for FY26

The primary agenda of the May 22, 2026 Board meeting is the consideration and approval of the audited financial results of the company for the year ended March 31, 2026. This is a mandatory disclosure requirement under applicable SEBI regulations, and the results, once approved, will be disseminated to the stock exchanges.

Dividend and Fund-Raising Plans

Alongside the financial results, the Board will consider the recommendation of a final dividend, if any, on the equity shares of the company for the year 2025-26. The Board will also take up enabling resolutions for raising funds through the following instruments:

Issue of Equity Shares including Convertible Bonds/Debentures through Qualified Institutional Placement (QIP)

Depository Receipts

Any other permissible modes

If the Board approves the fund-raising resolution, the matter will subsequently be placed for shareholders' approval at the ensuing Annual General Meeting (AGM).

Regulatory Compliance

The intimation has been filed in compliance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates prior notice to stock exchanges before Board meetings where financial results or dividend recommendations are to be considered. The notice was addressed to both BSE Limited and the National Stock Exchange of India Ltd.

Torrent Pharmaceuticals Limited successfully concluded an NCLT convened meeting of equity shareholders on April 28, 2026, where shareholders approved the proposed scheme of amalgamation with J. B. Chemicals & Pharmaceuticals Limited. The meeting marks a significant milestone in the consolidation process between the two pharmaceutical companies.

Meeting Details and Proceedings

The NCLT convened meeting was conducted through video conferencing and other audio-visual means, commencing at 10:00 a.m. IST and concluding at 10:21 a.m. IST on April 28, 2026. Mahesh Gupta, appointed as Chairman for the NCLT convened meeting, presided over the proceedings with the requisite quorum being present.

Meeting Parameter: Details Date: April 28, 2026 Start Time: 10:00 a.m. IST End Time: 10:21 a.m. IST Mode: Video Conferencing/Audio-Visual Means Chairman: Mahesh Gupta

Amalgamation Scheme Approval

The proposed scheme of amalgamation between J. B. Chemicals & Pharmaceuticals Limited (Transferor Company) and Torrent Pharmaceuticals Limited (Transferee Company) received approval from equity shareholders with the requisite majority. The approval was secured under the provisions of Section 230(6) of the Companies Act, 2013, which requires majority of equity shareholders and three-fourths in value of equity shareholders who cast their votes.

The voting process was conducted through both remote e-voting and e-voting at the meeting, ensuring compliance with the Companies Act, listing regulations, and circulars issued by the Ministry of Corporate Affairs. This dual voting mechanism provided shareholders with flexible participation options while maintaining regulatory compliance.

Regulatory Compliance and Next Steps

Torrent Pharmaceuticals has committed to disclosing the detailed results of remote e-voting and e-voting at the meeting along with the scrutinizer's report to stock exchanges separately. This disclosure will be made as required under Regulation 44(3) of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

The company communicated the meeting proceedings to both BSE Limited and National Stock Exchange of India Limited in compliance with Regulation 30 of the listing regulations. The successful approval of the amalgamation scheme represents a crucial step forward in the merger process between the two pharmaceutical entities.

Corporate Information

Torrent Pharmaceuticals Limited, incorporated with CIN L24230GJ1972PLC002126, operates from its registered office at Avirat, Thaltej Shilaj Road, Ahmedabad. The company maintains active communication channels for investor services and continues to ensure transparent disclosure of material developments to stakeholders and regulatory authorities.

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.

As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.

We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.

This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.

The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.

We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.

This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.

By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.

We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.